Table 2.
Baseline characteristics of the study and the control groups
| Characteristic | Study group | Control group | p value |
|---|---|---|---|
| No. of patients | 52 (100) | 26 (100) | |
| Sex | |||
| Female | 15 (29) | 5 (19) | |
| Male | 37 (71) | 21 (81) | |
| Agea | 60.3 ± 10.8 (33–79) | 61.3 ± 10.5 (33–80) | 0.71 |
| Body mass indexa | 27.5 ± 5.9 (16.0–40.9) | 27.4 ± 6.1 (16.0–37.9) | 0.95 |
| Sagittal abdominal diameter at the level of the portal vein bifurcation (cm)a | 25.6 ± 4.1 (18.2–36.7) | 25.2 ± 4.0 (18.3–31.2) | 0.69 |
| Tumour type | |||
| Hepatocellular carcinoma | 32 (61) | 20 (77) | |
| Intrahepatic cholangiocarcinoma | 3 (6) | 1 (4) | |
| Secondary liver cancer | 17 (33) | 5 (19) | |
| No. of lesions | 0.49 | ||
| 1 | 13 (25) | 9 (35) | |
| 2 | 8 (15) | 4 (15) | |
| 3 | 8 (15) | 4 (15) | |
| > 3 | 23 (45) | 9 (35) | |
| No. of segments affected | 0.34 | ||
| 1 or 2 | 24 (46) | 14 (54) | |
| 3 or 4 | 9 (17) | 3 (12) | |
| > 4 | 19 (37) | 9 (35) | |
Except where indicated, data represent numbers of patients and numbers in parentheses are percentages
aData represented as mean ± standard deviation (range)